RT Journal Article
SR Electronic
T1 The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e000921
DO 10.1136/jitc-2020-000921
VO 8
IS 2
A1 Ascierto, Paolo A
A1 Bifulco, Carlo
A1 Galon, Jerome
A1 Garbe, Claus
A1 Khleif, Samir N
A1 McQuade, Jennifer
A1 Odunsi, Kunle
A1 Okada, Hideho
A1 Paulos, Chrystal M
A1 Quezada, Sergio A
A1 Tawbi, Hussein A
A1 Timmerman, John
A1 Trinchieri, Giorgio
A1 Butterfield, Lisa H
A1 Puzanov, Igor
YR 2020
UL http://jitc.bmj.com/content/8/2/e000921.abstract
AB As part of the 2019 Immunotherapy Bridge congress (December 4–5, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on six topical issues in immunotherapy today. These were the use of chimeric antigen receptor T cell therapy in solid tumors, whether the Immunoscore should be more widely used in clinical practice, whether antibody-dependent cellular cytotoxicity is important in the mode of action of anticytotoxic T-lymphocyte-associated protein 4 antibodies, whether the brain is immunologically unique or just another organ, the role of microbiome versus nutrition in affecting responses to immunotherapy, and whether chemotherapy is immunostimulatory or immunosuppressive. Discussion of these important topics are summarized in this report.